In the high-stakes world of inflammatory bowel disease (IBD) research, breakthroughs are rare and incremental. For Crohn’s disease in particular, where treatment gaps remain wide despite a growing pipeline of biologics and small molecules, progress often comes in carefully measured steps.

The latest comes from Evinature, whose CurQD® formulation has already been studied in ulcerative colitis. Now, new data show its promise for Crohn’s as well.

Presented at ECCO 2025 and Digestive Disease Week, two of the most influential gatherings in gastroenterology, this retrospective, real-world study is the first to focus exclusively on Crohn’s patients, and the results are promising.  And while it does not replace the need for larger clinical trials, its results are a significant early sign that CurQD® may fill a gap in care.

Why This Study Matters

CurQD®, a proprietary nutraceutical that combines curcumin and Qing Dai to activate the Aryl Hydrocarbon Receptor (AhR), has already demonstrated benefits for IBD (Inflammatory Bowel Disease) patients, primarily those with ulcerative colitis. 

This research is significant because it focuses exclusively on Crohn’s patients. All of these patients had already tried several other IBD medications but hadn’t achieved remission and continued to experience disease symptoms. For patients and physicians, this makes the findings especially relevant: They show how CurQD can be used as an add-on therapy to IBD medications in order to optimize the therapeutic effect and bring patients into remission.

Key Results at 8 to 12 Weeks

The study followed patients for an initial 8–12 week induction period. The results were striking:

• 76% of patients experienced clinical response, meaning noticeable improvement in symptoms. 
• 75% showed a significant drop in fecal calprotectin (FCP), a marker of gut inflammation.
• 55% achieved full biomarker remission, with inflammation levels returning to normal.

These numbers are notable in Crohn’s, a disease where many patients lose response to conventional medications over time. For those who have cycled through biologics or small molecules without success, a nutraceutical approach showing this level of real-world response is a breakthrough signal.

Durability Beyond the First Weeks

Another meaningful outcome of the study was durability. 84% of patients who improved in the first 8-12 weeks continued to see benefits for months afterward, up to 26 months. This long-term retention matters because patients often face treatment fatigue, switching between therapies that can lose effectiveness. Since the majority stayed on CurQD® and continued to do well, it suggests tolerability and patient confidence in the treatment.

Safety and Long-Term Retention

Equally important, no unexpected safety concerns were reported. For many patients, the ability to stay on CurQD® over time was just as meaningful as the initial improvements. The ability to stay on CurQD® long-term without major side effects adds weight to its potential role in care.

What This Means for Patients

For those living with Crohn’s disease, who often cycle through therapies that may lose effectiveness, these findings point to a new and potentially reliable option. While biologics and advanced therapies remain cornerstones of care, they do not work for everyone, and may even lose effectiveness over time.

CurQD® is not intended to replace those drugs, but this study suggests they may complement them, offering a new avenue for patients who have run out of options or want to add an integrative approach.

The findings also underline a trend in IBD management: patients and physicians are increasingly open to therapies that bridge conventional medicine and plant-based science, provided they demonstrate proven, measurable results. In this case, patients not only reported feeling better, but also showed objective reductions in inflammation, pointing to a dual benefit that is rare in alternative therapies.

A Promising Step, With More to Come

The early results are encouraging, showing that CurQD® may help people with Crohn’s disease feel better and reduce inflammation. While more research is needed to confirm these benefits, this study marks an important first step.

For patients, it’s hopeful news: an option that may complement existing treatments and offer support where other therapies fall short. As CurQD® becomes more widely used, researchers will continue studying it to learn more about who benefits most and how it can fit into long-term care.

For now, it represents a new and promising approach worth keeping an eye on.